Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
The Sanford Guide, recognized as the essential reference for infectious disease treatment, announced the release of its first mobile app for the iPhone, iPod touch and iPad. The Sanford Guide App, available on Apple’s App Store for $29.99, contains the comprehensive guidelines and recommendations featured in the well-known pocket-size guides used by health care professionals in treatment decision making for over 40 years.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sanfordguide/50808/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
Turning your clocks ahead an hour on March 8 for the start of Daylight Savings Time may be known as the unofficial start to spring, but for many, it’s known as the day we lose an hour of sleep. As you prepare to change your clocks on Sunday, take that opportunity to evaluate your sleeping habits. The loss of that hour of sleep can turn minor sleep issues into major ones.
“When we move our clock forward or backward, our internal clock becomes out of sync with the external time,” says Dr. Daniel Shade, Board Certified Sleep Specialist and Director of the AHN Sleep Disorders Center. “The best way to combat this is to expose ourselves to light and let our bodies resynchronize.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447951-remworks-daylight-savings-sleep-coach/
Me at the 2 manual Nicholson and Lord organ at Reedswood Methodist Church in Walsall, West Midlands. Im giving this little instrument the theatre organ treatment with "Peanut vendor". Reedswood was one of the churches in the former Bloxwich and Willenhall Circuit that I used to play at in the evenings when I was organist at Allens Rough Methodist Church, Willenhall.
The Raynaud’s Association, a 501(c)3 non-profit health organization, is launching a new and assertive campaign – “Don’t Turn a Cold Shoulder to Painful Fingers” – to urge those with the painful disorder – and their doctors – not to dismiss the pain Raynaud’s sufferers endure.
October is Raynaud’s Awareness Month, when temperatures generally get chillier and an estimated 5-10 percent of the population experiences numbness and pain in their fingers, toes and other extremities. Stress can also trigger the condition.
To view the multimedia release go to:
https://www.multivu.com/players/English/8396551-raynauds-association-october-raynauds-awareness-month/
Under the leadership of the National Organization for Rare Disorders (NORD), the primary organization in the U.S. representing people with rare diseases, millions of Americans will gather tomorrow to observe the 5th annual Rare Disease Day. This international observance unites people around the globe to focus attention on the estimated 300 to 350 million patients worldwide afflicted with rare diseases and to recognize that their needs are a global public health concern. In the U.S., a rare disease is one that affects fewer than 200,000 Americans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60507-nord-rare-disease-day
PTSD treatment 1 week on former Birmingham soldier Craig Burgess talks about the changes in his PTSD post traumatic stress disorder and how all the nightmares and flashbacks have stopped after just one session with Birmingham NLP hypnotherapist Debbie Williams. Get a free hypnosis recording Stop worrying and create a wonderful life form here http://www.debbiewilliamsassociates.co.uk/home.htm
A short Clip from: BBC's Horizon Special Psychedelic Experience
One would not expect Britain's traditionally conservative and oft-staid BBC to screen a 50 minute film on the new wave of psychedelic research in humans. Yet, astonishingly enough, such a state of affairs recently came to pass. Before it aired on February 27th, 1997, Psychedelic Science was heavily featured in the media, even getting elaborate treatment in the Radio Times, a mass publication as institutionalised as the BBC itself. The Times, the Guardian, and the Independent, Britain's three leading broadsheets, all carried major pieces announcing the film.
Dr. Deborah Mash and her research with ibogaine was also treated in depth in the film. Mash explains how ibogaine can be used to break cocaine habits although, as with ayahuasca, we do not not learn much about the actual phenomenology induced by ibogaine - suffice it to say that patients experience transformative insights into themselves which can break their patterns of addiction.
Some addicts may have a long history of ADHD
btw
The history of ADHD
http://adhd-npf.com/english-adhd-history-1798-alexander/
is not so new... and many addicts seems to have some of it...
http://adhd-npf.com/history-of-adhd-1902-sir-george/
